Preliminary safety tolerability & efficacy results of KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in combination with Nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

被引：0
|
作者：
Xu, Binghe [1 ]
Li, Qiao [1 ]
Zhang, Qingyuan [2 ]
Zhang, Yue [2 ]
Ouyang, Quchang [3 ]
Zhang, Yang [4 ]
Liu, Qiang [5 ]
Sun, Tao [6 ]
Xu, June [7 ]
Yang, Jing [7 ]
Yang, Yue [7 ]
Luo, Xin [7 ]
Kong, Paul [7 ]
Xu, Ting [7 ]
机构：
[1] Canc Hosp Chinese Acad Med Sci, Beijing, Peoples R China
[2] Harbin Med Univ Canc Hosp, Harbin, Peoples R China
[3] Hunan Canc Hosp, Changsha, Peoples R China
[4] Liaocheng Peoples Hosp, Liaocheng, Shandong, Peoples R China
[5] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangzhou, Peoples R China
[6] Liaoning Canc Hosp, Dalian, Peoples R China
[7] Jiangsu Alphamab Biopharmaceut Co Ltd, Suzhou, Peoples R China
来源：
CANCER RESEARCH | 2021年 / 81卷 / 13期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1660
引用
收藏
页数：2
相关论文
共 50 条
  • [41] First findings from SYNERGY, a phase I/II trial testing the addition of the anti-CD73 oleclumab (O) to the anti-PD-L1 durvalumab (D) and chemotherapy (ChT) as first line therapy for patients (pts) with metastatic triple-negative breast cancer (mTNBC)
    Eiger, D.
    Maurer, C.
    Brandao, M.
    Aftimos, P. G.
    Punie, K.
    Taylor, D.
    Van den Mooter, T.
    Poncin, R.
    Canon, J-L.
    Duhoux, F.
    Casert, V.
    Clatot, F.
    Velghe, C.
    Craciun, L.
    Paesmans, M.
    de Azambuja, E.
    Ignatiadis, M.
    Larsimont, D.
    Piccart, M.
    Buisseret, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S386 - S387
  • [42] Combination of insulin-like growth factor-1 receptor/insulin receptor (IGF1R/IR) antagonist with anti-PD-L1 antibody blocks triple-negative breast cancer (TNBC) progression
    Hamilton, Nalo M.
    Marquez-Garban, Diana C.
    Burton, Lorena P.
    Comin-Anduix, Begonya
    Garcia, Alejandro J.
    Vadgama, Jaydutt V.
    CANCER RESEARCH, 2020, 80 (16)
  • [43] Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer
    Fumet, Jean-David
    Isambert, Nicolas
    Hervieu, Alice
    Zanetta, Sylvie
    Guion, Jean-Florian
    Hennequin, Audrey
    Rederstorff, Emilie
    Bertaut, Aurelie
    Ghiringhelli, Francois
    ESMO OPEN, 2018, 3 (04)
  • [44] PPAB001, a novel bispecific antibody against CD47 and CD24, enhances anti-PD-L1 efficacy in triple-negative breast cancer via reprogramming tumor-associated macrophages towards M1 phenotype
    Yang, Yun
    Li, Jianqin
    Zhang, Jing
    Wu, He
    Yang, Yan
    Guo, Huaizu
    Zhang, Dapeng
    Ge, Chunpo
    Zhou, Bei
    Ma, Ling
    Dong, Weihua
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 144
  • [45] Mario-3 phase II study safety run-in evaluating a novel triplet combination of eganelisib (formerly IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)
    Hamilton, Erika
    Lee, Arielle
    Swart, Rachel
    Newton, Gina
    O'Connell, Brenda
    Roberts, Jennifer
    Zhang, Halle
    Soliman, Hatem
    CANCER RESEARCH, 2021, 81 (04)
  • [46] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer
    Kalinsky, Kevin
    O'Shaughnessy, Joyce
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Tolaney, Sara M.
    Santin, Alessandro D.
    Abramson, Vandana
    Shah, Nikita C.
    Govindan, Serengulam V.
    Maliakal, Pius
    Sharkey, Robert M.
    Wegener, William A.
    Goldenberg, David M.
    Mayer, Ingrid A.
    CANCER RESEARCH, 2018, 78 (04)
  • [47] BEGONIA: Phase Ib/II open-label, platform study of safety and efficacy of durvalumab, paclitaxel and other novel oncology therapy agents as first-line (1L) therapy in patients with metastatic triple negative breast cancer (mTNBC)
    Schmid, P.
    Nunes, A. T.
    Lall, R.
    D'Cruz, C.
    Grinsted, L.
    Lanasa, M. C.
    CANCER RESEARCH, 2019, 79 (04)
  • [48] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Yau, T.
    Cosman, R.
    Aghmesheh, M.
    Moore, M.
    Chan, S. L.
    Mant, A.
    Eek, R.
    Zielinski, R.
    Li, P.
    Wang, H.
    Ma, Y.
    Tse, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1437 - S1438
  • [49] Preliminary safety and efficacy results from phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with anti-PD-1 mAb CS1003 in patients with advanced solid tumors
    Bishnoi, S.
    Cosman, R.
    Moore, M.
    Eek, R.
    Mant, A.
    Zielinski, R.
    Chan, L. S.
    Ma, Y.
    Zhang, Q.
    Yau, T.
    Aghmesheh, M.
    Tse, A. N.
    ANNALS OF ONCOLOGY, 2021, 32 : S840 - S840
  • [50] Safety and efficacy of the oral PARP inhibitor olaparib (AZD2281) in combination with paclitaxel for the first- or second-line treatment of patients with metastatic triple-negative breast cancer: Results from the safety cohort of a phase I/II multicenter trial.
    Dent, R. A.
    Lindeman, G. J.
    Clemons, M.
    Wildiers, H.
    Chan, A.
    McCarthy, N. J.
    Singer, C. F.
    Lowe, E. S.
    Kemsley, K.
    Carmichael, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345